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ABSTRACT 
To evaluate the clinical relevance of testing pituitary-ovarian re- 
sponses in patients suffering from polycystic ovary syndrome (PCOS) 
with the GnRH agonist nafarelin, a 1.2-mg dose of nafarelin was given 
intranasally to 19 women with PCOS and 15 healthy premenopausal 
women. The subsequent analysis of steroids in both serum and urine 
during the test was carried out at several time points for up to 24 h. 
Serum levels of 17a-hydroxyprogesterone were elevated at all 
time points of the test in PCOS patients US. controls [at baseline, 
3.5?0.2vs. 1.8t0.1nmol/L(P<0.001);at24h,9.9~0.9us.4.9~ 
0.3 nmoVL (P < O.OOl)]. Basal levels of androstenedione were 
higher in the patient group, but there was no significant change during 
the test in either group. Serum testosterone levels were also found to 
differ in PCOS patients compared with the control values at baseline (2.2 
? 0.2 us. 1.5 2 0.1 nmol/L; P < 0.05) and after nafarelin treatment (at 
24 h, 3.2 -t 0.4 us. 1.8 2 0.2 nmol/L; P < 0.05). Serum estradiol levels rose 
significantly in both groups during the test; the posttest levels were 
significantly higher in PCOS than in controls. 
The PCOS patients displayed a significant increase in androgen 
and gestagen metabolites as well as in glucocorticoid metabolites 
excreted in the urine during the 24 h. In the control subjects, except 
for 17a-hydroxypregnanolone, which rose significantly, none of the 
urinary steroids investigated showed relevant changes during the 
nafarelin test. The posttest excretion of allo-tetrahydrocortisol(1.4 + 
0.2 US. 0.3 5 0.1 pmol/g creatinine; P < 0.001) and the increase in 
17a-hydroxypregnanolone excretion (1.4 + 0.2 us. 0.3 -t 0.1 Fmol/g 
creatinine; P < 0.001) were distinctly higher in PCOS patients than 
in the controls; the diagnostic sensitivity of the combination of both 
parameters was 89% at a 93% specificity. Thus, measurements of 
17@-hydroxyprogesterone levels in serum and of urinary allo-tetra- 
hydrocortisol and 17cY-hydroxypregnanolone after nafarelin treat- 
ment make this stimulation test a valuable diagnostic tool for iden- 
tifying PCOS patients. The significant changes in the excretion of 
urinary androgen and gestagen metabolites, unmasked by GnRH 
agonist stimulation, suggest a functional alteration of the pituitary- 
ovarian axis. The reason for the increased excretion of glucocorticoid 
metabolites after nafarelin stimulation remains to be clarified. (JClin 
Endocrinol Metab 80: 280-288, 1995) 
P OLYCYSTIC ovary syndrome (PCOS) is an endocrin- opathy commonly associated with menstrual irregu- 
larities; anovulatory infertility; skin manifestations such as 
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A: androstenedione (androst-4-ene-3,17-dione); AD: androstanediol 
(3a,l7P-dihydroxy-5c-androstane); ADG: androstane-diol glucuronide 
(3ol,l7P-dihydroxy-5cY-androstane 3-glucuronide); ADT: androsterone 
(3cu-hydroxy-5a-androstan-17-one); ADTG: androsterone glucuronide 
(3a-hydroxy-5a-androstan-17.one 3-glucuronide); CORT: cortolone 
(3o1,17a,20&,21-tetrahydroxy-5P-pregan-ll-one); PCORT: p-cortolone 
(3a,17a,20a,21-tetrahydroxy-5P-pregnan-ll-one); DHEA: dehydroepi- 
androsterone (3/3-hydroxyandrost-5-en-17-one); DHEAS: dehydroepi- 
androsterone-sulfate (3P-hydroxyandrost-5-en-17-one 3-sulfate); E: cor- 
tisone (17a,21-dihydroxypregn-4-ene-3, 11,20-trione); E2: 17P-estradiol 
(3, 17/3-dihydroxyestra-1, 3, 5(10)-triene); ET: 3a-eliocholanolone (3~ 
hydroxy-5P-androstan-17.one); F: cortisol (lip, 17~~, 21 trihydroxy- 
pregn-4-ene-3, 20-dione); FAI: free androgen index; IRMA: immunora- 
acne, alopecia, or hirsutism; hyperinsulinemia; and obesity 
(l-5). The syndrome is clinically heterogeneous, exhibiting a 
broad spectrum of phenotypes (4,5). The diagnosis of PCOS 
has been made by histological identification of multiple fol- 
licular cysts and thecal cell hyperplasia (21, usually in en- 
larged ovaries (4), although this is not a requirement for the 
clinical diagnosis. Polycystic ovaries are easily recognized by 
ultrasound, but as they are found in other disorders as well 
as in normal women, the finding of polycystic ovaries alone 
is not sufficient to make the diagnosis of PCOS. 
diametric assay; PD: pregnanediol (5P-pregnane-3cu,20(-dial); PROG: 
progesterone (pregn-4-ene-3,20-dione)-; 17HPROG: (17~hydroxy- 
progesterone (17~hydroxypregn-4-ene-3,20-dione); 17HPREG: 17a-hy- 
droxy-pregnanolone (3a,17cz, dilhydroxy-5P-pregnan20-one); PT: (3c~, 
17c~, 20cr-trihydroxy-5P-pregnane); RIA: radioimmunoassay; SHBG: sex 
hormone-binding globulin T: testosterone (17P-hydroxyandrost-4-en-3- 
one); THE: tetrahydrocortisone (3a,l7a,21-trihydroxy-5p-pregnane- 
11,20-dione; THF: tetrahydrocortisol (3a,ll&17a,21-tetrahydroxy-5P- 
pregnan-20-one); aTHF: allo-tetrahydrocortisol (3a,llp,17a,21-tetra- 
hydroxy-5a-pregan-20-one); THS: tetrahydro-ll-deoxyxortisol (3a,17a, 
21-trihydroxy-5P-pregnan-20-one). 
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The etiology of the disorder is still a subject of controversy. 
There are lines of evidence suggesting that PCOS is a form 
of functional ovarian hyperandrogenism, triggered by go- 
nadotropin-dependent mechanisms (6, 7). One explanation 
of this phenomenon is the estrone hypothesis (8,9), accord- 
ing to which permanent hyperestronemia is thought to sen- 
sitize the pituitary (9, 10) and cause an increase in LH se- 
cretion. As a result, thecal-interstitial cells are stimulated to 
hyperplasia, leading to an excess secretion of androstenedi- 
one (A) and other androgens. An elevation in unbound or 
free estradiol (E2) has also been suggested to be a contribu- 
tory factor (11). These and other theories are not mutually 
exclusive. More recently, defects in different enzyme systems 
regulating the steroid pathway have been thought to initial- 
ize the pathophysiological conditions for PCOS. One of the 
underlying defects is thought to be an increase in the activity 
of skin and hepatic 5a-reductase (12, 13), resulting in an 
augmented conversion of testosterone (T) to dihydrotestos- 
terone (14). In gas chromatography steroid profiles, this re- 
sults in higher ratios of 5o-tetrahydrocortisol (aTHF)/SP- 
tetrahydrocortisol (THF) and 5a-androsterone (5aADT)/ 
5P-etio-cholanolone (5PET) in urine (14). Rodin et al. (15) 
found an increased adrenal secretion of cortisol due to an 
augmented adrenocortical activity in women with PCOS 
caused by increased activity of 11 P-hydroxysteroid dehy- 
drogenase (11/3HSDH), entailing an altered interconversion 
of cortisol (F) to cortisone (E). Thus, the enhanced cortisol 
clearance rate brings about an increase in the synthesis of 
adrenal androgens. Another explanation for the functional 
ovarian hyperandrogenism might be a dysregulated ovarian 
cytochrome P45Oc17a enzyme complex (17a-hydroxylase 
plus 17,20 lyase activity) (16). Based on this hypothesis, a 
specific biochemical diagnostic test for this disorder has been 
established by analyzing the specific stimulation of the pi- 
tuitary-ovarian axis by GnRH agonists (GnRHa). Barnes et al. 
(6) and Ehrmann et al. (7) first used the GnRHa [6-D-(2- 
naphthyl)alanine]GnRH (nafarelin)] to stimulate pituitary 
and gonadal secretion in PCOS patients. This agonist is 200- 
fold more effective in stimulating the pituitary-gonadal axis 
than endogenous GnRH (17, 18). Compared with those in 
healthy individuals, women suffering from this disorder dis- 
play patterns of basal and stimulated levels of serum LH, 
FSH, and 17a-hydroxyprogesterone (17HPROG) similar to 
those in men. A masculinized pituitary and ovarian response 
to a GnRHa stimulus, therefore, implies that the cytochrome 
P45Oc17a enzyme complex within the ovarian thecal-inter- 
stitial cells has become hyperfunctional. 
In addition to the pathological response to nafarelin and 
the related GnRHa buserelin (191, biochemical findings in 
PCOS patients normally include either an increased concen- 
tration of serum LH or an increased LH/FSH ratio (5, 20). 
Hyperandrogenemia is characteristic in the syndrome and is 
often reflected clinically as hirsutism. The basal serum levels 
of the androgens T, A, and dehydroepiandrosterone sulfate 
(DHEAS; suppressible with dexamethasone) are elevated 
(21-25). Furthermore, ADT and androstanediol glucuronides 
and sulfates (metabolites of dihydrotestosterone) are often 
found to be elevated (34-36). Hyperinsulinemia and insulin 
resistance are also found in both the lean and, more pro- 
nouncedly, the obese PCOS patients (26-30). This together 
with the increased androgen levels leads to a suppression of 
sex hormone-binding globulin (SHBG) in serum (31, 32). 
PCOS patients have also been reported to have increased 
urinary free F or F metabolite levels (14, 15, 33). 
As the value of the diagnostic test presented by Barnes et 
al. (6) has yet to be evaluated, the question arises of whether 
additional urinary steroid metabolite determinations during 
the course of the stimulation would be helpful to increase the 
diagnostic efficiency of the test. Regarding the high resolu- 
tion gas chromatography analyses of unstimulated steroid 
concentrations in urine of PCOS patients reported by Rodin 
et al. (15), it would seem worthwhile to apply this technique 
in patients stimulated with the nafarelin test protocol. The 
aim of our study, therefore, is to evaluate the nafarelin test 
as a diagnostic tool for PCOS by measuring a subset of 
stimulated steroid metabolites in both the serum and urine 
of affected patients. In contrast to the original protocol using 
100 pg SC administered nafarelin (6), an intranasal applica- 
tion of 1.20 mg nafarelin was chosen. Additionally, we in- 
vestigated the metabolic changes in serum and urinary ste- 
roids involved in adrenal and gonadal steroidogenesis. 
Besides the well known alterations in serum hormone levels, 
we document here significant changes in urinary steroid 
levels, especially with regard to androgens, gestagens, and 
corticoids, unmasked by the ovarian stimulation test. 
Subjects and Methods 
Subjects 
Nineteen women with PCOS and 15 healthy women with regular 
menses every 26-32 days were recruited for this study. All subjects were 
assumed to be free of acute or chronic disease based on a medical 
examination and clinical chemistry. Informed consent was obtained 
from all subjects. The study was approved by the ethical committees of 
the Ludwig-Maximilians University and the Technical University of 
Munich. Women with PCOS were patients admitted to the gynecological 
departments of the university hospitals of Grosshadern and Rechts der 
Isar; the clinical data of all subjects are given in Table 1. 
The patients were diagnosed as having PCOS on the basis of the 
typical ultrasound features combined with two or more of the following 
clinical and biochemical criteria: 1) hirsutism (Ferriman-Gallwey score, 
>6), 2) infertility (duration of 2 yr minimum, after exclusion of other 
causes), 3) oligo/amenorrhea, and 4) free androgen index (FAI,T/SHBG 
X 100) greater than 7. Typical sonographic features included multiple 
cysts (0.5-0.8 cm in diameter), arranged either peripherally or scattered 
throughout the ovarian stroma of the facultatively enlarged ovaries (34). 
Pelvic ultrasound examinations were performed with a 5-megahertz 
240-degree phased array vaginal endoprobe (Combison 310, Kretz, Zipf, 
Austria) by two investigators (T.S. and C.H.). Exclusion criteria for both 
the PCOS patients and the controls were 1) thyroid dysfunction, 2) 
hyperprolactinemia (PRL, >570 mILJ/L; third international standard 
84/5001, 3) late-onset congenital adrenal hyperplasia (17HPROG in- 
TABLE 1. Clinical characteristics of PCOS patients and controls 
PCOS patients Controls 
ige (a) 
BMI 
Hirsutism grading 
(Ferriman-Gallweyl 
Menstrual pattern 
Regular 
Oligomenorrhea 
Amenorrhea 
28.1 19 k 1.1 29.5 15 -c 1.5 
26.4 i- 1.5 21.1 k 0.4 
7.5 -t 1.1 2.0 -c 0.4 
3 15 
5 
11 
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crease, >45 nmol/L after adrenocortical stimulation with 0.25 mg 
ACTH), 4) endocrine-active tumors, 5) hormonal replacement therapy or 
oral contraceptives within the last 3 months, and 6) controls were ex- 
cluded if they had polycystic ovaries on ultrasound. 
Nafarelin test 
The nafarelin test was performed in a modification of the original 
protocol (6); GnRHa was administered intranasally instead of SC (37). To 
each study subject, six sniffs (three sniffs in each nostril) of 0.23 mg 
nafarelin acetate (Synarela, Syntex Pharma, Aachen, Germany), equiv- 
alent to a total of 1.20 mg nafarelin, were administrated. The bioavail- 
ability of intranasally applied nafarelin is 3% (17, 18), and the serum 
half-life is 4.4 h. All subjects were admitted to the ward on the morning 
of the test between 0800-1000 h between the third to sixth day of the 
menstrual cycle, if present. All subjects collected a pretest 24-h urine 
sample. Blood samples were drawn 15 min before and 0, 2,4, and 24 h 
after nafarelin administration, and a second 24-h urine sample was 
collected with the time set from time zero. All blood and urine specimens 
were centrifuged at 2000 X g and frozen at -20 C until analyzed. No 
serious side-effects were observed during our study. 
Hormonal analysis in serum 
Steroid measurements were performed in duplicate, using the fol- 
lowing assays [in parentheses are indicated the manufacturer, interassay 
coefficient of variation (CV), mean, and lower detection limit (DL)I: T, 
RIA [Immuchem, Carson, CA; CV, 9.7%; mean, 25.3 nmol/L (n = 34); 
DL, 0.52 nmol/LJ; A, RIA [Diagnostic Systems Laboratories, Webs- 
ter, TX; CV, 18.6% (n = 10); mean, 5.6 nmol/L (n = 10); CV, 9.0%; mean, 
30.1 nmol/L (n = 10); DL, 0.18 nmol/LJ; E,, enzyme immunoassay 
[Boehringer Mannheim, Mannheim, Germany; CV, 12.1%; mean, 118 
pmol/L (n = 6); CV, 9.9%; mean, 2364 pmol/L (n = 6); DL, 20 pmol/LJ; 
DHEAS, RIA [Diagnostic Products Corp., Los Angeles, CA; CV, 10.2%; 
mean, 4.9 wmol/L (n = 13); CV, 5.0%; mean, 15.9 wmol/L (n = 13); DL, 
0.13 Fmol/L]; 17HPROG, RIA [Diagnostic Products; CV, 16.3%; mean, 
12.1 nmol/L (n = 13); DL, 0.30 nmol/LJ; SHBG, immunoradiometric 
assay [Farmos Group, Oulunsalo, Finland; CV, 6.8%; mean, 40 nmol/L 
(n = 9); DL, 2.5 nmol/LJ; LH, chemiluminescence immunoassay [CLIA; 
Kodak Clinical Diagnostics, Amersham, United Kingdom; CV, 4.0%; 
mean, 18.8 mIU/mL (n = 12); DL, 0.5 mIU/mLJ; FSH, CLIA [Kodak; CV, 
2.6%‘; mean, 9.0 mIU/mL (n = 12); DL, 0.9 mIU/mLJ; androstanediol 
glucuronide (ADG), RIA [Diagnostic Systems Laboratories; CV, 5.6%; 
mean, 16.6 nmol/L (n = IO); DL, 0.6 nmol/LJ; F (in serum), CLIA 
[Kodak; CV, 3.8%; mean, 574 nmol/L (n = 8); DL, 13 nmol/Ll; F (free 
in urine), fluorescence polarization immunoassay without sample ex- 
traction [Abbott Laboratories, Irving, TX; CV, 6.1%; mean, 397 nmol/L 
(n = 26); DL, 25 nmol/L; the cross-reactivity of the specific anti-F 
antibody to E is I.l%]; and progesterone (PROG), CLIA [Kodak; CV, 
5.3%; mean, 6.0 nmol/L (n = 12); DL, 0.5 nmol/LJ. ADT glucuronide 
(ADTG) was determined according to the method previously described 
(35). 
Steroid analysis in urine 
Apprafus. For capillary gas chromatographic (GC) analyses, a model 
3700 GC (Varian, Darmstadt, Germany) was used. Separations were 
obtained on a 30-m DB-1 fused-silica capillary column (internal diam- 
eter, 0.32 mm; J & W Scientific, Folsom, CA). The carrier gas was helium 
at a flow rate of 2.2 mL/min. The injector temperature was set at 290 C; 
the column temperature isothermal was 150 C for 5 min, then 150-300 
C with a heating rate of 2 C/min; the flame ionization detector tem- 
perature was 320 C; the splitting ratio was 1:20. A Mega-Integrator 
D-2500 (Merck, Darmstadt, Germany) was used as system controller. 
The reagents /3-glucuronidase and arylsulfatase (type H-2, crude solu- 
tion from Helix porn&n), as well as the reference steroid compounds, and 
the hydrocarbon calibrators C,, (n-docosane), C,, (n-tetracosane), and 
C,, (?I-dotriacontane) were obtained from Sigma (Deisenhofen, Germa- 
ny). N-Methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) was ob- 
tained from Fluka (Buchs, Switzerland), and cortolone (CORT) from 
Makor (Jerusalem, Israel). All other laboratory chemicals were pur- 
chased from Merck. Sep-Pak cartridges with C,, and NH, materials were 
obtained from Millipore-Waters (Eschborn, Germany). For sample prep- 
aration, l/lOOth of the 24-h urine was used for analysis. After the 
addition of 50 pg 3PET (3p-hydroxy-5P-androstan-17-one) as an internal 
standard, the pH was adjusted to 4.6 with 3 mol/L boric acid-acetate 
buffer. The mixture was adsorbed on a Sep-PakC,, cartridge (38), which 
was primed twice with 5 mL methanol and twice with 5 mL water. The 
cartridge was eluted twice with I-mL portions of methanol, the eluate 
was evaporated at 50 C under vacuum, and the residue was dissolved 
in 100 PL methanol, 10 mL water, 1 mL 0.2 mol/L sodium acetate buffer 
(pH 5.2), and 100 PL P-glucuronidaselarylsulfatase solution (100,000 
U/mL glucuronidase and 5,000 U/mL sulfatase; U = modified Fishman 
unit). Hydrolysis was then performed at 55 C for 2 h (39). The hydro- 
lyzed residue was adsorbed again on a Sep-Pak C,, cartridge. One gram 
of anhydrous sodium sulfate was placed on the top of a NH, cartridge, 
and the C,, cartridge was connected on the top of this (40). The cartridges 
were eluted with two portions of 1.5 mL ethyl acetate-methanol (9:1, 
vol/vol). Twenty micrograms each of C,,, C,,, and C,, hydrocarbons 
dissolved in 100 ILL II-hexane were added as calibrators for the retention 
indices to the eluate, and the solvents were then evaporated. The de- 
rivatization was performed with 50 PL MSTFA and 100 PL pyridine 
containing 10 mg sodium acetate at 70 C for 24 h (41). Two microliters 
were used for GC analysis. This procedure of derivatization fully con- 
verts 17.keto groups into enol-trimethylsilyl ethers and hydroxy groups 
into trimethylsilyl derivatives, with the exception of Il-hydroxy and 
1 I-keto groups. 
Peak identification: By coinjection of authentic steroid compounds (ex- 
tracted in parallel with the urine samples), the methylene units of the 
relevant steroids were calculated and used to identify the peaks. Con- 
firmation of steroid identity, when necessary, was assessed by GC/mass 
spectrometry techniques. 
Peak quantification: The steroid concentrations found in urine were 
calculated from peak area ratios related to the internal standard 3PET 
and expressed as micromoles of steroid per g creatinine in the respective 
urines. 
A typical urinary steroid profile of a PCOS patient performed using 
the GC technique applied is shown in Fig. 1. The overall interassay CV 
for all steroids measured was 4.5% (n = 6). 
Statistical analysis 
Statistical analyses were calculated using the BMDP386 package (ver- 
sion 7.0, BMDP Statistical Software, Los Angeles, CA). Initial plots of 
several steroid parameters showed skewed distributions, precluding the 
assumption of normal data distributions, and therefore, we used a non- 
parametric test panel in an exploratory evaluation. Hormone variables 
between the groups were compared by use of the Mann-Whitney rank 
sum test; the intragroup changes during the test were compared by use 
of either the Wilcoxon test (applied for urinary analytes) or the Friedman 
test (applied for serum analytes). Optimal cut-off values for the distinc- 
tion of the steroid analytes 17HPROG, 17a-hydroxypregnanolone 
h 
FIG. 1. Typical urinary steroid profile from a PCOS patient, per- 
formed by use of the GC technique. 
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(17HPREG), and allo-tetrahydrocortisol (aTHF) between PCOS patients 
and controls were derived from receiver-operating characteristic plots. 
All results are presented as the mean 5 SEM. 
Results 
Serum levels of gonadotropins and steroids 
The intranasal application of nafarelin resulted in a sig- 
nificant rise in serum LH and FSH levels (P < 0.001) in all 
women (PCOS patients and controls). For both gonado- 
tropins, peak levels occurred after 4 h. Two patients showed 
increasing concentrations of LH or FSH even up to the last 
measurement at 24 h. In all women tested with nafarelin, the 
levels of LH and FSH at 24 h were higher than the respective 
basal pretest values. As shown in Table 2, there were no sig- 
nificant differences between controls and PCOS patients in 
basal or stimulated LH or FSH levels. The LH/FSH ratio, how- 
ever, was significantly higher in PCOS patients than in controls 
24 h after GnRHa application (2.6 + 0.4 us. 1.6 ‘- 0.1; P < 0.05). 
Serum 17HPROG levels were elevated at all time points in 
PCOS patients compared with those in control subjects (P < 
0.001). The baseline level of 17HPROG in PCOS patients was 
3.5 2 0.2 compared to 1.8 + 0.1 nmol/L in the controls. In 
both groups, 17HPROG and its precursor, PROG, rose sig- 
nificantly during the test (P < 0.001; Table 2 and Fig. 2); the 
rates of increase in 17HPROG were similar in the two groups. 
At baseline, no difference was seen in the serum levels of 
PROG between the groups. 
o-4 0-H 
Oh 2h 4h 24h Oh 2h 4h 24h 
Hours after nafarelm applicatm Hours after nafarelin application 
-c- Controls - PCOS 
FIG. 2. Responses of 17HPROG (a) and A (b) to nafarelin in sera of 
PCOS patients and controls. Serum concentrations are given as the 
mean k SEM. Significant differences between PCOS and controls are 
indicated: **, P < 0.01; ***, P < 0.001. 
Basal serum A levels were higher in PCOS patients than 
in controls (9.2 ? 0.3 VS. 6.2 + 0.5 nmol/L; P < 0.001). Neither 
the PCOS patients nor the controls exhibited a significant 
change in A levels during the test (Table 2). Similar to those 
of A, the basal serum levels of T were elevated in PCOS 
patients compared to the control values (2.2 + 0.2 US. 1.5 + 
0.1 nmol/L; P < 0.05). Only in the PCOS patients was a 
significant rise in T observed during the test (at 24 h, 3.2 + 
0.4 VS. 1.8 -t 0.2 nmol/L; P < 0.01). SHBG levels were lower 
in the PCOS patients than in the controls (data not shown). 
Therefore, the FAI levels were significantly higher in the 
PCOS patients, both basally and during the course of the 
TABLE 2. Mean values and ranges ( ~SEM) for serum parameters in the course of the nafarelin test for PCOS patients and controls after 
intranasal nafarelin application 
GPXlD Parameter Basal 0 h Post 2 h Post 4 h Post 24 h 
62.2 t 6.5 
23.5 ? 2.0 
2.7 t 0.3 
22.1 k 2.6” 
13.7 2 1.4” 
1.6 k 0.1“ 
Controls LH W/L) 4.1 k 0.5 35.5 ? 4.1 
FSH W/L) 5.5 t 0.5 13.9 2 1.1 
LH/FSH ratio 0.8 k 0.1 2.6 k 0.3 
A (nmoVL) 
T (nmol/L) 
FAI (%I 
DHEAS (ymol/L) 
PROG (nmol/L) 
17HPROG (nmol/L) 
ADG (nmol/L) 
ADTG (nmol/L) 
Es (pmoLW 
F (nmol/L) 
6.2 2 0.5 
1.5 ? 0.1 
3.0 f 0.4 
6.1 + 0.5 
1.6 2 0.2 
1.8 k 0.1 
9.0 2 1.2 
162 k 26.9 
6.0 2 0.5 6.1 ? 0.5 6.6 t 0.6 
1.8 rf- 0.2 
3.6 2 0.5b 
6.1 k 0.5 
2.8 2 0.5” 
4.9 k 0.3” 
1.4 k 0.1 1.4 2 0.1 
2.7 + 0.3 2.7 2 0.3 
6.2 + 0.6 
1.6 2 0.2 
2.0 k 0.1 
9.0 k 1.1 
6.3 + 0.6 
1.7 + 0.2 
2.2 5 0.1 
9.4 t- 1.1 9.5 k 1.2 
166 k 30.3 
591 k 67” 
218 2 17 
33.0 + 6.5” PCOS patients LH (NJ/L) 
FSH (W/L) 
LH/FSH ratio 
A (nmol/L) 
T (nmol/L) 
FAI (%) 
DHEAS (pmol/L) 
PROG (nmol/L) 
17HPROG (nmoVL) 
ADG (nmol/L) 
ADTG (nmol/L) 
1112 18 
257 2 27 209 2 23 199 k 32 
37.7 + 4.2 62.2 + 7.2 5.6 k 0.8 
6.0 + 0.4 
1.0 + 0.1 
9.2 2 0.3d 
2.2 2 0.2” 
12.8 2 3.6’ 
6.3 2 0.7 
1.7 ? 0.3 
13.3 + 1.1 
3.0 ? 0.3 
20.5 + 1.6 12.3 + 1.2” 
3.3 5 0.4 2.6 k 0.4”,’ 
8.8 2 0.6’ 9.0 + 0.5’ 9.7 k 0.6’ 
3.2 2 0.4c,f 
18.1 2 5.F’ 
6.4 + 0.8 
2.2 2 0.2’ 2.1 + 0.2’ 
12.5 2 3.8’ 13.8 + 4.5’ 
6.4 2 0.7 6.6 2 0.7 
1.8 2 0.4 2.3 k 0.5 
3.9 k 0.3d 4.7 5 0.4d 
8.5 t 1.4 8.4 k 1.4 
3.4 t 0.8” 
9.9 k 0.9”,d 3.5 t 0.2d 
8.9 k 1.5 9.8 5 1.6’ 
231 2 27.2 
950 k 123”,’ 
360 k 38’ 
216 k 25.6 
132 + 11 
378 + 27’ 283 k 21’ 
E, (pmollL) 
F (nmol/L) 281 k 23” 
a P < 0.001, significant changes in the course of the nafarelin test (Friedman test). 
b P < 0.05, significant changes in the course of the nafarelin test (Friedman test). 
‘P < 0.05, PCOS us. controls (Mann-Whitney test). 
d P < 0.001, PCOS us. controls (Mann-Whitney test). 
e P < 0.01, PCOS vs. controls (Mann-Whitney test). 
fP < 0.01, significant changes in the course of the nafarelin test (Friedman test). 
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test [at baseline, 12.8 k 3.6% zx. 3.0 + 0.4% (P < 0.01); at 
24 h, 18.1 + 5.5% DS. 3.6 + 0.5% (P < O.Ol)l. E, levels rose 
significantly (P < 0.001) in both groups during the test; the 
posttest levels were significantly higher in PCOS than in 
controls (950 + 123 VS. 591 + 67 pmol/L; P < 0.05). 
Neither serum DHEAS, ADG, nor ADTG concentrations 
showed any significant differences when comparing PCOS and 
controls. Although ADG levels increased as a result of nafarelin 
stimulation (P < 0.05), no changes in the serum concentrations 
of ADTG or DHEAS were observed (Table 2). 
Serum F levels were higher in PCOS patients than controls 
at all time points (P < 0.01 at 0 and 24 h; P < 0.05 at 2 and 
4 h). Due to the dynamic fluctuations in serum F during the 
day, the Friedman test was not applied to the different values 
of the two groups. 
Levels of steroids in the 24-h urine samples 
The results of the steroid profiles for both the PCOS pa- 
tients and the controls during the nafarelin test are shown in 
Table 3. In the controls, only 17HPREG levels were signifi- 
cantly stimulated (P < 0.05) by nafarelin; all other steroid 
levels remained unchanged. In PCOS patients, however, 
there were significant increases in urinary androgen de- 
rivatives (ADT and ET), gestagens [17HPREG and preg- 
nanetriol (PT)] and glucocorticoids [tetrahydrocortisone 
(THE), THF, CORT, and p-cortolone (PCORT)] including 
free F (see Table 3 for significances). With respect to the 
differences observed between the patients and controls, 
the following parameters were higher at baseline: THE (P 
< 0.05), aTHF (P < 0.5), ADT/ET ratio (P < 0.05), and 
aTHF/THF ratio (P < 0.01). Ratios of ADT/ET and aTHF/ 
THF may be considered to be indirect measures of 5a- 
reductase activity. After stimulation, the following pa- 
rameters were higher in PCOS patients: ADT (P < O.Ol), 
17HPREG (P < 0.05), PT (P < 0.05), THE (P < 0.05), THF 
(P < 0.05), aTHF (P < O.OOl), ADT/ET ratio (P < 0.05), 
corticoid sum (= CORT + /3CORT + THE + THF + aTHF) 
(P < 0.05), and free F (P < 0.05). Significant stronger 
increases over 24 h were found in urine from PCOS pa- 
tients for ADT, ET, 17HPREG, PT, CORT, THF, and free F 
TABLE 3. Mean values and ranges (+SEM) for urine parameters pre- and postnafarelin testing for PCOS patients and controls 
GIXXlp 
Controls 
Parameter 
ADT 
ET 
DHEA 
17HPREG 
PD 
PT 
THS 
CORT 
PCORT 
THE 
THF 
aTHF 
ADT/ET ratio 
THE/THF ratio 
aTHFPTHF ratio 
Cart.-sum 
F 
PCOS patients ADT 
ET 
DHEA 
17HPREG 
PD 
PT 
THS 
CORT 
PCORT 
THE 
THF 
aTHF 
ADT/ET ratio 
THE/THF ratio 
aTHF/‘l’HF ratio 
Cart.-sum 
F 
Pretest Posttest 
7.4 k 0.8 7.2 k 0.8 
11.5 k 1.3 
2.9 ? 0.8 
1.3 z 0.3 
10.4 t- 2.2 
3.5 + 0.3 
0.8 + 0.1 
4.1 + 0.3 
2.9 + 0.2 
9.5 + 0.7 
5.3 k 0.5 
11.3 2 1.2 
2.2 i 0.4 
1.6 ? 0.3 
9.4 z 2.0 
3.6 2 0.3 
0.7 k 0.1 
3.9 2 0.3 
2.7 k 0.2 
9.9 I! 0.8 
5.4 k 0.4 
1.8 2 0.1 1.8 k 0.1 
0.7 k 0.1 0.7 k 0.1 
1.91 2 0.14 1.86 t 0.09 
0.37 k 0.04 0.34 + 0.02 
23.6 2 1.6 23.7 + 1.6 
256 k 19 261 + 17 
10.0 lr 0.9 13.4 t 1.56 
10.7 + 0.7 14.9 k 1.8 
3.9 + 1.3 3.5 i- 1.0 
1.3 + 0.2 2.6 k 0.3" 
6.4 + 1.2 8.2 k 1.5 
4.1 + 0.4 6.1 2 0.7" 
0.6 k 0.1 0.8 2 0.1 
4.5 2 0.6 5.6 + 0.8 
2.5 2 0.3 3.6 k 0.5 
12.1 2 0.9" 16.4 k 2.1" 
5.7 k 0.5 8.1 2 0.9" 
2.8 2 0.3d 3.4 k 0.4' 
1.0 ? 0.1” 1.0 2 0.1” 
2.23 f  0.12" 2.03 2 0.10 
0.52 + 0.05' 0.45 t 0.05 
27.6 + 2.1 37.2 + 4.3d 
279 k 19 350 t 25d 
Difference 
-0.2 + 0.3 
-0.2 + 0.6 
-0.8 i- 0.7 
0.3 k 0.1” 
-1.0 2 1.0 
0.1 -t 0.2 
-0.2 k 0.1 
-0.2 k 0.3 
-0.2 + 0.2 
0.4 + 0.4 
0.1 + 0.4 
0.0 + 0.1 
-0.05 k 0.14 
-0.03 ? 0.04 
0.1 t 1.1 
5 t- 19 
3.3 k l.Oh,’ 
4.3 2 1 5”,” 
0.1 + 0:9 
1.4 2 0.2’J 
1.7 + 1.3 
1.9 5 0.5h.f 
0.3 k 0.2 
1.1 2 0.5Q.d 
1.1 k 0.4" 
4.2 2 1.8" 
2.4 k 0.9'*d 
0.6 k 0.3 
-0.24 2 0.10" 
-0.08 k 0.03'~" 
9.4 + 3.7" 
72 + 25",d 
All parameters, except ratios and F, are given as micromoles per g creatinine; F is given as nanomoles per g creatinine. Cart.-sum, 
CORT + pCORT + THE + THF + aTHF. 
a P < 0.05, pre- US. postnafarelin (Wilcoxon test). 
’ P < 0.01, PCOS us. controls (Mann-Whitney test). 
c P < 0.01, pre- US. postnafarelin (Wilcoxon test). 
d P < 0.05, PCOS US. controls (Mann-Whitney test). 
’ P < 0.001, PCOS us. controls (Mann-Whitney test). 
f  P < 0.001, pre- US. postnafarelin (Wilcoxon test). 
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compared to those in the healthy controls. The most prom- 
inent differences between the two groups were found for 
the increase in 17HPREG levels (1.4 + 0.2 US. 0.3 -t 0.1 
pmol/g creatinine; P < 0.001) and the poststimulation 
value of aTHF (3.4 2 0.4 US. 1.8 + 0.1 pmollg creatinine; 
P < O.OOl), as shown in Fig. 3. Tetrahydro-1 I-deoxycortisol 
(THS), a derivative of the F precursor ll-deoxycortisol, 
was found only in low concentrations in both patients and 
controls, and significant differences or changes could not 
be determined. In contrast to PT (a derivative of 
17HPROG), no significant differences or changes were 
seen in pregnanediol (I’D) levels, which is a product of 
PROG. 
The ratio of THE/THF, an indicator of the 1lPHSDH 
activity and similar to the ratio of the ll-0x0/11-hydroxy 
metabolites of F was significantly different (P < 0.05) in 
PCOS patients us. controls at baseline, whereas in the 
course of the test, the PCOS patients showed a significant 
decrease (P < 0.05). 
Calculation of sensitivities and specificities of several ana- 
lytes in the course of the test revealed that, based on 93% 
specificity, the posttest 17HPROG level in serum has a sen- 
sitivity of 89% (cut-off value, 6.4 nmol/L), whereas in urine, 
the posttest aTHF level shows a sensitivity of 78% (cut-off 
value, 2.26 pmol/g creatinine), and the difference value of 
17HPREG shows a sensitivity of 72% (cut-off value 0.8 
pmol/g creatinine). The sum of both urinary parameters 
resulted in a sensitivity of 89% (cut-off value, 2.8 kmol/g 
creatinine). 
Additionally, correlations between the urinary steroid me- 
tabolites were determined. In the patient group, there were 
significant positive correlations between the following post- 
test parameters: 17HPREG correlates with THE, THF, CORT, 
/3CORT, ADT, ET, and PT; and PT correlates with CORT, 
PCORT, THE, THF, ET, and ADT. The respective P values 
varied between less than O.OOl(l7HPREG US. PT or PT US. ET) 
and 0.013 (17HPREG VS. CORT). No significant correlations 
were observed in the control group. - 
34 34 3c) 
Ia Controls 
12 
cl PCOS 
FIG. 3. Box and whisker plots (graphical displays of the data distri- 
butions) of the posttest levels of aTHF (a; 11, the difference values of 
17HPREG (b; 2), and the combination of both (c; 1 + 2) in urine of 
PCOS patients and controls undergoing nafarelin testing. The box 
and whisker plot presentation shows themedian, 25-75s range, and 
extremes (without outliers). Significant differences between PCOS 
and controls are indicated: *, P; 0.05; **, P < 0.01; ***, P < 0.001. 
The serum and urine test parameters described above were 
not significantly different in lean and obese PCOS subjects. 
Discussion 
The use of basal hormone levels, LH/FSH ratios, elevated 
androgen levels, or pelvic ultrasound examinations often fail 
to give reliable diagnostic indications for PCOS. The nafare- 
lin test, developed by Barnes ef al. (6), was the first test to 
assess suitable biochemical criteria for the diagnosis. The 
GnRHa nafarelin is a potent specific stimulator of the pitu- 
itary-gonadal axis; given as a single dose, it is much more 
potent than the commonly used GnRH. A short term stim- 
ulation test using this drug appears to be a useful tool in 
distinguishing PCOS from other causes of hyperandro- 
genism in women (7). Our study, using an intranasal appli- 
cation with pharmacodynamically equivalent doses, has con- 
firmed these data concerning levels of 17HPROG and the 
gonadotropins in serum. In addition, we were able to document 
significant changes in urinary steroid metabolite levels, espe- 
cially in those of androgens, gestagens, and corticoids. 
In accordance with the data described by Barnes et al. (6), 
we found that the maximal gonadotropin responses in serum 
occurred after 4 h, whereas the ovarian steroid responses 
continued to rise during the entire 24-h test period. The 
LH/FSH ratio was clearly elevated in the patients at 24 h, as 
expected for this disorder. The most distinctive increase was 
that found for 17HPROG. In contrast to the findings of Barnes 
et al. (6), we observed no significant change in A in either the 
PCOS patients or controls, although the respective levels 
were higher in the patient group throughout. In contrast T 
together with A, a product of the P45Oc17o enzyme complex, 
was found to be elevated in the PCOS patients compared to 
control levels and underwent a significant increase during 
the test in the patients. Of the T metabolites ADG and ADTG, 
only ADG significantly increased during the test in the PCOS 
patients. The observation that the concentration of ADTG 
remained unchanged in PCOS patients together with a mar- 
ginally elevated T level can be explained by the fact that in 
our patient group the androgen excess was only moderate 
and the mean Ferriman-Gallwey index for the group of 19 
patients was 7.5. Serum DHEAS, the main adrenal androgen 
parameter, showed no changes during the test in either 
group. The E, response to nafarelin was exaggerated in PCOS 
patients compared to the controls. 
These data give rise to the suggestion that cytochrome 
P450c17a may be dysregulated in the PCOS patients. Nev- 
ertheless, with regard to the serum T concentrations of the 
affected patients, increased activities of both the ovarian 
17cy-hydroxylase and 17,20-lyase enzymes in the A4-steroid 
pathway cannot be ruled out. In addition to the diagnostic 
discrimination afforded by baseline parameters such as 
17HPROG (with a sensitivity of 78% at 93% specificity; cut- 
off value, 2.5 nmol/L), only the posttest serum levels of 
17HPROG allow a further distinction to be drawn between 
PCOS patients and controls with a sensitivity of 89% at 93% 
specificity (cut-off value, 6.4 nmol/L). 
Applying the high resolution GC technique using the 
MSTFA derivatization method to the urine samples, we were 
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able to quantify the abnormal steroidogenic response to na- 
farelin in the affected patients. The examination of the re- 
spective steroid profiles in the test subjects revealed a quite 
different pattern in the PCOS patients compared to the con- 
trols. In healthy women, only 17HPREG, the urinary deriv- 
ative of 17HPROG, showed an significant increase during the 
test. In patients, however, there was a significant increase in 
the urinary metabolites of androgens (ADT and ET), gesta- 
gens (17HPREG, PD, and PT), and glucocorticoids (THE, 
THF, aTHF, CORT, pCORT, and F). 
In our study, the urinary steroid profiles revealed greater 
5aTHF/5PTHF and ADT/ET ratios in PCOS patients (Fig. 4). 
This is in accordance with the report of Stewart et al. (141, who 
demonstrated increased 5cY-reductase activity in the liver and 
44 1 .o 
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FIG. 4. Box and whisker plots of the 5a-reductase ratios of aTHF/ 
THF (a) and ADT/ET (b) in urine of PCOS patients and controls before 
and after nafarelin testing. The box and whisker plot presentation 
shows the median, 25-75% range, and extremes (without outliers). 
Significant differences between PCOS and controls are indicated: *, 
P < 0.05; **, P < 0.01; ***, P < 0.001. 
skin of patients suffering from this endocrine disorder. In the 
course of the nafarelin test, however, only the aTHF/THF- 
ratio is altered, due to an increase in aTHF levels; the origin 
of this increased 5Lu-reductase activity level in PCOS is still 
under debate. According to Rosenfield (42), the overproduc- 
tion of ovarian androgens seems to result in a stimulation of 
this enzyme in skin and liver (12,131. The borderline change 
in aTHF secretion in urine that was observed (P = 0.07) also 
suggests that the enhanced 5a-reductase activity may be the 
result of androgen excess and not due to a primary mech- 
anism, as reported by Stewart et al. (14). 
According to Giagulli et al. (12), ADG appears to be a better 
parameter for determining peripheral 5cY-reductase activity 
than ADT. Therefore, it would be necessary to determine the 
levels of urinary androstanediol, rather than ADT, to confirm 
our model. This, however, was not possible with the GC 
technique applied in this study due to peak interferences. 
It can be stated that the basal serum F level and basal free 
F level in urine are slightly elevated in PCOS patients com- 
pared with those in controls. This may be due to a preexisting 
alteration in adrenal corticoid secretion. Invitti et al. (33) 
documented an increased urinary free F level in PCOS pa- 
tients and suggested that an overactive hypothalamic-pitu- 
itary-adrenal axis might be responsible. Rodin et al. (15) re- 
ported increased adrenal secretion of F due to an augmented 
adrenocortical activity in women with PCOS, but decreased 
urinary free F levels. The exaggerated glucocorticoid excre- 
tion in PCOS patients after naferelin treatment, however, is 
surprising and could be explained by an increased oxidation 
of F to E due to a dysregulated llPHSDH, which is not 
accounted for by obesity. As a result of the enhanced F 
clearance rate, the synthesis of adrenal androgens is aug- 
mented. In our study, the THE/THF ratio was significantly 
higher in PCOS patients us. controls at baseline (P < 0.05), 
which is in agreement with the ratio of the ll-oxo/ll-hy- 
droxy metabolites of F reported by Rodin et al. (15). In the 
course of the test, however, the PCOS patients showed a 
decrease in this ratio, which results in a loss of significance 
in the differences between the ratios in PCOS and control 
subjects. Therefore, it can be suggested that the abnormal 
1lPHSDH activity is attenuated in the course of the GnRHa 
test. Due to a reduced conversion of F to E, the excretion of 
the respective F and corticosterone metabolites increases 
acutely over the 24-h test period. Our hypothesis is that the 
excess production of E, released by the gonadotropin surge 
in PCOS patients us. controls is able to attenuate the 
1lPHSDH activity. Together with an increased metabolism 
of 17HPROG toward PT, this would explain the increased 
corticoid excretion in urine and the absence of a parallel 
increase in A and T in relation to 17HPROG in serum during 
the GnRHa test. Another possible explanation for the en- 
hanced glucocorticoid excretion in PCOS patients after na- 
farelin application is that the gestagen surge that results from 
GnRHa stimulation displaces serum F from corticosteroid- 
binding globulin and leads to an augmented F metabolism. 
It has previously been described that serum corticosteroid- 
binding globulin levels are significantly decreased in PCOS 
patients (33). 
Therefore, our data suggest that an altered interconversion 
of F and E is able to play a role in PCOS, as suggested for the 
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augmented/dysregulated ovarian cytochrome P450c17a ac- 
tivity. The proportion and importance of the proposed en- 
zyme dysregulation in the pathogenesis of PCOS have yet to 
be proven, because measurements of basal serum levels of 
11-hydroxyandrostenedione, a marker of adrenal androgen 
secretion, support the idea that the ovaries and not the adre- 
nals are the major source of androgens in PCOS (5). Addi- 
tionally, divergent results concerning the elevation of 
DHEAS levels in PCOS patients have previously been de- 
scribed (22,23,43,44) and argue against a pivotal role of the 
adrenal glands in the etiology of this disorder. However, an 
altered sensitivity of the adrenal cortex to corticotropin, ev- 
idenced by higher ll-hydroxyandrostenedione levels after 
stimulation with corticotropin-releasing factor and an in- 
creased metabolic clearance of F and corticosterone, appears 
to be a supplementary symptom of the pathophysiological 
changes in PCOS. 
One additional observation from our study is that, inter- 
estingly, in the PCOS patients, no significant differences in 
urinary steroid concentrations between the lean and obese 
patients could be found during the test. This would appear 
to rule out the idea that increased F production rates in 
obesity cause higher secretion rates of E in the adipose tissue 
of PCOS patients. 
This study, undertaken with 19 PCOS patient and 15 con- 
trols, documents the efficiency of the nafarelin test in con- 
firming the ovarian abnormality in PCOS suspected by the 
clinical diagnosis. The more practical intranasal application 
mode together with the measurements of urinary steroids 
gives an effective diagnostic tool for investigating this en- 
docrine disorder. The study suggests that 17HPROG levels 
in serum together with those of aTHF and 17HPREG in urine 
are the best discriminatory parameters of the GnRHa stim- 
ulation test. An additional investigation concerning these 
three parameters should confirm our results by the applica- 
tion of confirmatory statistical analysis. 
The sensitivity of the test, as defined by the ability to detect 
an ovarian abnormality, was 89% for both the posttest level 
of 17HPROG in serum and the combination of the difference 
value of 17HPREG and the posttest value of aTHF in urine 
(all at a 93% specificity). Further studies are necessary to 
determine whether a combination of the nafarelin stimula- 
tion test with, for example, short term dexamethasone sup- 
pression, is capable of distinguishing between the different 
forms of hyperandrogenism in women. 
Due to the variability of symptoms displayed by patients 
suffering from this endocrine disorder, additional investi- 
gation is required to confirm whether the suggested dys- 
regulated enzyme systems, such as 11 PHSDH or cytochrome 
P45Oc17c~, are alone sufficient to cause PCOS or whether 
other ovarian and/or adrenal factors play a role in the patho- 
genesis. In addition, the reason for the exaggerated corticoid 
excretion in the course of the nafarelin stimulation is in need 
of clarification. 
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